BIOS — Biosenic SA Share News
0.000.00%
Last trade - 00:00Brief: Biosenic: Autoimmune Disease Platform Has Completed Phase IIB Trial
Brief: Bone Therapeutics Changes Name To Biosenic, Following The Acquisition Of A Majority Participation Of Medsenic Valued At EUR 40 Million
Brief: Bone Therapeutics To Regain Worldwide Rights To ALLOB
Brief: Bone Therapeutics H1 Operating Loss For Period Narrows To EUR 4.0 Million
Brief: Bone Therapeutics To Acquire Medsenic And Become BioSenic
Brief: Bone Therapeutics Introduces Interim Analysis In Phase IIB Tibial Fractures Study
Brief: Bone Therapeutics End-March Net Cash At EUR 6.0 Mln
Brief: Bone Therapeutics: Subscription Agreement For A Maximum EUR 5 Mln Convertible Bonds Facility With ABO
Brief: Bone Therapeutics Enters Into Exclusive Reverse Merger Discussions With Medsenic
Brief: Bone Therapeutics FY Operating Loss Narrows To EUR 12.0 Million
Brief: Bone Therapeutics Secures 5 Million Euros Financing
Bone Therapeutics shares slide on strategic turnaround
Brief: Bone Therapeutics Says ALLOB Talks Are Longer Than Anticipated
Bone Therapeutics slumps after fourth quarter update
Brief: Bone Therapeutics Sees 2021 Net Cash Burn At 16-18 Million Euros
French and Benelux stocks-Factors to watch
Brief: Bone Therapeutics Announces Closing Of Private Placement
Brief: Bone Therapeutics Raises 3.3 Million Euros In Private Placement
Bone Therapeutics shares shoot up on deal with Link Health